AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28586529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-individual difference in change in plasma glucose between testing days after second exercise session
Number of subjects: 8
Study 25073879 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) + Methotrexate (MTX)
Number of subjects: 779
Study 25073879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + Methotrexate (MTX)
Number of subjects: 779
Study 23962543 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐HOPE intervention (twice‐daily infant stimulation using ATVV and four maternal participatory guidance sessions plus two telephone calls)
Number of subjects: 198
Study 23962543 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐HOPE intervention
Number of subjects: 198
Study 23962543 — intervention group
Group type: COMPARATOR
Intervention: Control group (attention control)
Number of subjects: 198
Study 21959024 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) guided treatment
Number of subjects: 319
Study 21959024 — intervention group
Group type: COMPARATOR
Intervention: Standard guidelines treatment
Number of subjects: 319
Study 18460288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular MRI
Number of subjects: 0
Study 18460288 — intervention group
Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement and microvascular obstruction imaging
Number of subjects: 0
Study 18460288 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of gadolinium enhancement, perfusion, and cine imaging
Number of subjects: 0
Study 18460288 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI in clinical trials of heart failure
Number of subjects: 0
Study 16847470 — intervention group
Group type: EXPERIMENTAL
Intervention: semisynthetic homoharringtonine (ssHHT) at a dose of 5 mg m(‐2) day(‐1) for 9 days
Number of subjects: 18
Study 16847470 — intervention group
Group type: EXPERIMENTAL
Intervention: semisynthetic homoharringtonine (ssHHT)
Number of subjects: 18
Study 14671165 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily for 2 years
Number of subjects: 241
Study 14671165 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 241
Study 14671165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 10071025 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance Biopsies (SB)
Number of subjects: 126
Study 10071025 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically Indicated Biopsies (CB)
Number of subjects: 126
Study 10071025 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Biopsy Procedures
Number of subjects: 126
Study 7747718 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day infusion of 30 mg/m2 of carboplatin (CBDCA) daily (Group A)
Number of subjects: 21
Study 7747718 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-day infusion of carboplatin (CBDCA) beginning from the first day of radiotherapy (Group B)
Number of subjects: 21
Study 7747718 — intervention group
Group type: COMPARATOR
Intervention: Both groups received conventional radiotherapy (RT) with total doses ranging from 65 to 70 Gy
Number of subjects: 21
Study 1675368 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets
Number of subjects: 92
Study 1675368 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis with maloprim
Number of subjects: 92
Study 1675368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 6271844 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 80
Study 6271844 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine
Number of subjects: 80
Study 31587470 — intervention group
Group type: EXPERIMENTAL
Intervention: Number-based game
Number of subjects: 148
Study 31587470 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory (WM) game
Number of subjects: 148
Study 31587470 — intervention group
Group type: COMPARATOR
Intervention: Control game
Number of subjects: 148
Study 31131616 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic blend containing Lactobacillus acidophilus NCFM (1010 cfu), Lactobacillus paracasei Lpc‐37 (2.5×10^9 cfu), Bifidobacterium animalis subsp. lactis strains Bl‐04 (2.5×10^9 cfu), Bi‐07 (2.5×10^9 cfu), and HN019 (1010 cfu)
Number of subjects: 156
Study 31131616 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 156
Study 28424260 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-phytate maize (LP; 1.6 mg/g)
Number of subjects: 22
Study 28424260 — intervention group
Group type: COMPARATOR
Intervention: Control maize (C; 7.1 mg/g)
Number of subjects: 22
Study 25918111 — intervention group
Group type: EXPERIMENTAL
Intervention: [(11)C]ORM‐13070 during ketamine infusion
Number of subjects: 8
Study 25918111 — intervention group
Group type: EXPERIMENTAL
Intervention: [(11)C]ORM‐13070 after atomoxetine combined with cold stimulation
Number of subjects: 8
Study 25918111 — intervention group
Group type: COMPARATOR
Intervention: Control PET scan with [(11)C]ORM‐13070
Number of subjects: 8
Study 23496375 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg daily for 6 months plus supportive therapy
Number of subjects: 31
Study 23496375 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment alone
Number of subjects: 31
Study 21124304 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 1000 mg
Number of subjects: 44
Study 21124304 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine 0.3 g/kg
Number of subjects: 44
Study 19952657 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct flow island flap
Number of subjects: 122
Study 19952657 — intervention group
Group type: COMPARATOR
Intervention: Reverse flow island flap
Number of subjects: 122
Study 19952657 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturing
Number of subjects: 122
Study 18089340 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 22
Study 18089340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15306704 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate 4 mg/kg followed by mefloquine 15 mg/kg simultaneously (group A)
Number of subjects: 360
Study 15306704 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate 4 mg/kg followed by mefloquine 15 mg/kg after 8 hours (group B)
Number of subjects: 360
Study 15306704 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate 4 mg/kg followed by mefloquine 15 mg/kg after 24 hours (group C)
Number of subjects: 360
Study 15306704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 11428736 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% ophthalmic solution twice daily adjunctive to loratadine 10 mg once daily
Number of subjects: 94
Study 11428736 — intervention group
Group type: COMPARATOR
Intervention: Loratadine 10 mg once daily
Number of subjects: 94
Study 11428736 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% ophthalmic solution plus loratadine 10 mg
Number of subjects: 94
Study 11428736 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine plus loratadine
Number of subjects: 94
Study 9600500 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nasal corticosteroids
Number of subjects: 20
Study 9600500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9037279 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 million units of interferon alpha-2b, instilled weekly for 12 weeks followed by once-monthly instillation for 1 year
Number of subjects: 90
Study 9037279 — intervention group
Group type: COMPARATOR
Intervention: Double-distilled water, used as control
Number of subjects: 90
Study 1773908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethindene maleate 3 mg
Number of subjects: 60
Study 1773908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethindene maleate 6 mg
Number of subjects: 60
Study 1773908 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate 12 mg
Number of subjects: 60
Study 1773908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7128568 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill test at various times of day
Number of subjects: 31
Study 31603205 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNSs until 6 mo postpartum, and SQ-LNSs for offspring (6 mg Fe/d) from 6 to 18 mo of age
Number of subjects: 1320
Study 31603205 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrient supplements until 6 mo postpartum
Number of subjects: 1320
Study 31603205 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid until delivery
Number of subjects: 1320
Study 31603205 — intervention group
Group type: EXPERIMENTAL
Intervention: LNS group (SQ-LNSs)
Number of subjects: 1320
Study 31603205 — intervention group
Group type: COMPARATOR
Intervention: Non-LNS group
Number of subjects: 1320
Study 31450014 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking pace of 2-2.9 mph
Number of subjects: 21919
Study 31450014 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking pace of 3-3.9 mph
Number of subjects: 21919
Study 31450014 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking pace of ≥4 mph
Number of subjects: 21919
Study 28065635 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-delivered meals and nutrition education for 10 days
Number of subjects: 21
Study 28065635 — intervention group
Group type: COMPARATOR
Intervention: Usual care and nutrition education
Number of subjects: 21
Study 23922290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led 6-month comprehensive pulmonary rehabilitation program
Number of subjects: 30
Study 23922290 — intervention group
Group type: COMPARATOR
Intervention: Conventional education (Control)
Number of subjects: 30
Study 24244703 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish Björknäs intervention (lifestyle intervention)
Number of subjects: 0
Study 21177724 — intervention group
Group type: EXPERIMENTAL
Intervention: PMEA-coated cardiopulmonary bypass circuits
Number of subjects: 30
Study 21177724 — intervention group
Group type: COMPARATOR
Intervention: Phisio-coated cardiopulmonary bypass circuits
Number of subjects: 30
Study 18817894 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantescal (Bionap, Italy)
Number of subjects: 60
Study 18817894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17138781 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit triage (n=728)
Number of subjects: 1459
Study 17138781 — intervention group
Group type: COMPARATOR
Intervention: Telephone triage (n=731)
Number of subjects: 1459
Study 14561987 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSC (filgrastim‐mobilized peripheral blood stem cell) donation
Number of subjects: 329
Study 14561987 — intervention group
Group type: COMPARATOR
Intervention: BM (bone marrow) donation
Number of subjects: 329
Study 14561987 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSC donation
Number of subjects: 329
Study 14561987 — intervention group
Group type: COMPARATOR
Intervention: BM donation
Number of subjects: 329
Study 11121633 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: 64 Gy RT + BCNU (80 mg/m2, days 1-3, 56-58, then 4 cycles every 8 weeks)
Number of subjects: 104
Study 11121633 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: 70.4 Gy RT + BCNU (80 mg/m2, days 1-3, 56-58, then 4 cycles every 8 weeks)
Number of subjects: 104
Study 11121633 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: 64 Gy RT + BCNU
Number of subjects: 104
Study 11121633 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: 70.4 Gy RT + BCNU
Number of subjects: 104
Study 8935450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive individual anti-smoking advice given in parallel with hospital antenatal care
Number of subjects: 0
Study 8935450 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1874201 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of ear and paravertebral points with small doses of fentanyl (mean 1.2 micrograms kg‐1)
Number of subjects: 29
Study 1874201 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose fentanyl (mean 22.9 micrograms kg‐1)
Number of subjects: 29
Study 6863224 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxapine (260 mg daily for 4 weeks)
Number of subjects: 142
Study 6863224 — intervention group
Group type: COMPARATOR
Intervention: doxepin (130 mg daily for 4 weeks)
Number of subjects: 142
Study 6863224 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxapine
Number of subjects: 142
Study 6863224 — intervention group
Group type: COMPARATOR
Intervention: doxepin
Number of subjects: 142
Study 31385755 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics-based machine learning model
Number of subjects: 21
Study 31385755 — intervention group
Group type: COMPARATOR
Intervention: Visual assessment
Number of subjects: 21
Study 31385755 — intervention group
Group type: COMPARATOR
Intervention: Area of low attenuation
Number of subjects: 21
Study 31385755 — intervention group
Group type: COMPARATOR
Intervention: Average Hounsfield unit
Number of subjects: 21
Study 28275998 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors related to access to care
Number of subjects: 367
Study 28275998 — intervention group
Group type: EXPERIMENTAL
Intervention: Insurance acceptance
Number of subjects: 367
Study 28275998 — intervention group
Group type: EXPERIMENTAL
Intervention: Online information about what other parents think of a practice
Number of subjects: 367
Study 28275998 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' interpersonal skills and pediatrician-specific traits
Number of subjects: 367
Study 26915823 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure (300 μg PM2.5/m(3) for 120 min)
Number of subjects: 27
Study 26915823 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA) exposure
Number of subjects: 27
Study 24875032 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 125
Study 24875032 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid
Number of subjects: 125
Study 24875032 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 125
Study 22939642 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight hyaluronic acid (HA)
Number of subjects: 40
Study 22939642 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-molecular weight hyaluronic acid (HA)
Number of subjects: 40
Study 19107596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilation
Number of subjects: 761
Study 19107596 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic myotomy
Number of subjects: 761
Study 17460334 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr)
Number of subjects: 24
Study 17460334 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) with Glycerol (Gly)
Number of subjects: 24
Study 17460334 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 24
Study 14691424 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 861
Study 14691424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 861
Study 11777361 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 70 years or older
Number of subjects: 902
Study 11777361 — intervention group
Group type: COMPARATOR
Intervention: Patients younger than 70 years
Number of subjects: 902
Study 11777361 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients after passing a spontaneous breathing trial
Number of subjects: 902
Study 11777361 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of 70 years or older
Number of subjects: 902
Study 9821527 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 30
Study 9821527 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 30
Study 9821527 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygeline
Number of subjects: 30
Study 7821201 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment with tissue-preserving substances (epinephrine +/- NaCl in 36%, fibrin glue +/- epinephrine in 24%)
Number of subjects: 1139
Study 7821201 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment with tissue-damaging procedures (epinephrine + polidocanol +/- NaCl in 26%, epinephrine + thermocoagulation in 7%)
Number of subjects: 1139
Study 7821201 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment after recurrent bleeding
Number of subjects: 1139
Study 7821201 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment after recurrent bleeding
Number of subjects: 1139
Study 7821201 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in high risk group (older than 60 years; high amount of bleeding)
Number of subjects: 1139
Study 7821201 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 1139
Study 7821201 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of patient
Number of subjects: 1139
Study 7821201 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoglobin < 8 g/dl on admission
Number of subjects: 1139
Study 7821201 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial severity of bleeding (Forrest group I)
Number of subjects: 1139
Study 7821201 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence of bleeding
Number of subjects: 1139
Study 2480926 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar tumor probe
Number of subjects: 30
Study 2480926 — intervention group
Group type: COMPARATOR
Intervention: Prosthetic tube
Number of subjects: 30
Study 4416359 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective shunt
Number of subjects: 0
Study 4416359 — intervention group
Group type: COMPARATOR
Intervention: Non-selective or total shunt
Number of subjects: 0
Study 31743896 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (physicians received baseline survey results)
Number of subjects: 53
Study 31743896 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (physicians did not receive baseline survey results)
Number of subjects: 53
Study 31743896 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 53
Study 30576507 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation (NVAS)
Number of subjects: 181
Study 30576507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 28359325 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 2200
Study 28359325 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccination at 14 weeks of age
Number of subjects: 2200
Study 26163828 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (STPP)
Number of subjects: 106
Study 26163828 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 106
Study 23649554 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) 100 µg/d
Number of subjects: 38
Study 21353211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lidocaine injection (group U/S)
Number of subjects: 200
Study 21353211 — intervention group
Group type: COMPARATOR
Intervention: Standard infiltration by manual palpation (group M)
Number of subjects: 200
Study 19691829 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of ciprofloxacin or 7 days of empirical beta-lactams +/− gentamicin intravenously with early switch to oral ciprofloxacin followed by 7 days of blinded placebo
Number of subjects: 400
Study 19691829 — intervention group
Group type: COMPARATOR
Intervention: 7 days of ciprofloxacin or 7 days of empirical beta-lactams +/− gentamicin intravenously with early switch to oral ciprofloxacin followed by 7 days of blinded ciprofloxacin
Number of subjects: 400
Study 16467702 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg roxithromycin daily for 3 months
Number of subjects: 64
Study 16467702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 12718812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools (community participation, peer education, public lectures, health clubs, training of STD treatment providers)
Number of subjects: 3754
Study 12718812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools
Number of subjects: 3754
Study 12718812 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 3754
Study 11275030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger 1 g per day for 4 days
Number of subjects: 70
Study 11275030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 9385881 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) for primary prevention of SCD
Number of subjects: 0
Study 9385881 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications used in heart failure
Number of subjects: 0
Study 8231601 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with Mycobacterium w
Number of subjects: 53
Study 8231601 — intervention group
Group type: COMPARATOR
Intervention: Micronized starch as placebo (Control)
Number of subjects: 53
Study 8231601 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine group
Number of subjects: 53
Study 8231601 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 8231601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 3524608 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine (DPA)
Number of subjects: 204
Study 3524608 — intervention group
Group type: COMPARATOR
Intervention: Control (no DPA)
Number of subjects: 204
Study 31625136 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoimmune conditions (systemic lupus erythematosus, polyarteritis nodosa, autoimmune hepatitis, myasthenia gravis, uveitis)
Number of subjects: 0
Study 31625136 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive drugs used to treat autoimmune conditions
Number of subjects: 0
Study 30002098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 97/103 mg twice daily
Number of subjects: 414
Study 30002098 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan 300 mg once daily
Number of subjects: 414
Study 30002098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 414